Install
Biotech
Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
- 9 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Aerospace
- Agriculture
- Banking (Industry)
- Computing
- Consumer Goods
- Defense
- Energy & Utilities
- Entertainment
- Food & Beverage
- Government
- Healthcare
- Real Estate (Commercial)
- Management & Consulting
- Manufacturing
- Technology
- Telecom
- Transportation & Logistics
- Automotive
- Construction
- Education & EdTech
- Hospitality & Travel
- Insurance (Industry)
- Mining & Materials
- Pharmaceuticals
Latest in Biotech
Veracyte acquiring Convergent Genomics in up to $180M deal
36+ min ago (22+ words) Veracyte to buy Convergent for $150M upfront, gaining UroAmp MRD urine test for early bladder cancer detection and monitoring. Read more here....
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push And Sepranolone Advancement
22+ hour, 20+ min ago (154+ words) Relmada Therapeutics is rated Hold as NVD-01 IND slips to 2026 despite strong NMIBC data; cash runway to 2029. Click here to read my latest analysis on RLMD stock. - Relmada Therapeutics is initiated at "Hold" due to delayed IND filing for lead…...
We're turning into a more innovative company: Teva Pharmaceuticals CEO Richard Francis
2+ hour, 10+ min ago (39+ words) Richard Francis, Teva Pharmaceuticals CEO short and pro, joins 'Power Lunch' to discuss the company's turnaround strategy, expanding its market access, its next growth leg, and more. We're turning into a more innovative company: Teva Pharmaceuticals CEO Richard Francis...
Cellectis Exits Two CAR-T Programs, Advances Gene Editing
20+ hour, 29+ min ago (140+ words) Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise → © OpenServe Holdings LLC Where do you stand? What each side asserts, disputes — or leaves out entirely. Whose framing of this story rings truest to…...
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
23+ hour, 29+ min ago (337+ words) NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on…...
Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
20+ hour ago (402+ words) First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeuticsPhase 1 si... Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases - First-in-class bispecific antibody designed for mast…...
ZS named a Leader in 2026 IDC MarketScape for Life Science R&D RWD and RWE
15+ hour, 9+ min ago (433+ words) EVANSTON, Ill., Sept. 14, 2026 /PRNewswire/ -- ZS, a global management consulting and technology firm, has been named a Leader in the IDC MarketScape: Worldwide Life Science R&D RWD/Real-World Evidence for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment (IDC # US54122226, [August]…...
C-CAMP National Bio Entrepreneurship competition 2026 recognises 15 startups and four student teams
18+ hour, 24+ min ago (509+ words) The winners were announced at the finale held in Bengaluru, in the presence of Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited Fifteen startups and four student teams have emerged as winners of the ninth edition of the C-CAMP National Bio Entrepreneurship…...
US push to cut drug prices could mean longer waits for European patients
16+ hour, 6+ min ago (942+ words) Last May, US President Donald Trump pushed to align drug pricing with the lowest levels among other developed nations — so-called most-favoured-nation (MFN) pricing. However, the pricing policy might have negative consequences. European patients might have to wait longer for some…...
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
17+ hour, 31+ min ago (484+ words) Definium Therapeutics to Discuss Topline Results from Phase 3 Pan The National Law Review Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK--(BUSINESS WIRE)…...